Thymosin peptides: what the class is

The word thymosin does not name a chemical family. It names a place where a set of peptides was first found. A calf thymus extract called thymosin fraction 5 was separated into its components, and thymosin alpha-1, polypeptide beta-1 and thymosin beta-4 came out of that separation^[1]. Those peptides are not structural relatives. That one historical label is why TB-500 and BPC-157 land in the same forum thread, the same vendor bundle and the same search query, even though only one of them is a thymosin at all.

One label, two unrelated molecules

Thymosin alpha-1 is 28 residues long. UniProt records it as residues 2 to 29 of prothymosin alpha, a 111-residue protein^[2]. Thymosin beta-4 is a separate gene product, 44 residues as translated, with the mature chain running from residue 2 to residue 44^[3]. Different genes, different lengths, different jobs. The beta-thymosins are the main intracellular G-actin sequestering peptides in most vertebrate cells, which is a structural role inside the cytoskeleton^[1]. Thymosin alpha-1 works on the immune system instead. Anyone reading a claim about thymosins as a group should ask which one, because the answer changes the pharmacology completely.

BPC-157 is not a thymosin

This is the correction the class page exists to make. BPC-157 is a pentadecapeptide, 15 amino acids, and the Zagreb research group behind most of its literature describes it as stable and native in human gastric juice^[4]. It comes from a gastric protein, Body Protection Compound, which is where the initials come from. It shares no sequence, no parent protein and no origin story with thymosin alpha-1 or thymosin beta-4. It is grouped with TB-500 because the two are sold into the same injury-recovery market and are frequently taken together, not because they share biochemistry. Our BPC-157 page treats it on its own terms, and the TB-500 page does the same.

The family member with real approvals is the one nobody markets

Thymosin alpha-1, sold as Zadaxin and known by the international non-proprietary name thymalfasin, is the outlier. Goldstein and Goldstein wrote in 2009 that it is approved in over 35 countries for the treatment of hepatitis B and C, and as an immune stimulant and adjuvant, and that it was then in late-stage clinical testing in the United States and Europe for hepatitis C and stage IV melanoma^[5]. Registered trial activity matches that picture. ClinicalTrials.gov returns 65 registered studies for thymalfasin, spanning COVID-19 vaccine response in older adults, non-small-cell lung cancer and pancreatic cancer^[6]. That is what a peptide looks like when sponsors have taken it through regulatory systems. Neither BPC-157 nor TB-500 has an approval anywhere in our coverage area, and neither has been approved by the FDA or the EMA.

TB-500 is a fragment, and the trials are for the whole molecule

Thymosin beta-4 is the major actin-sequestering molecule in eukaryotic cells, with a documented role in dermal and corneal wound healing^[7]. TB-500 is not that molecule. Doping-control chemists analysed a TB-500 product in 2012 and identified in it the N-terminally acetylated 17 to 23 fragment of human thymosin beta-4, Ac-LKKTETQ^[8]. That heptapeptide sits inside the full sequence^[3] and covers the actin-binding stretch, but a fragment is not the parent peptide, and the published human work used the parent. ClinicalTrials.gov returns 18 registered studies for thymosin beta 4^[9], and the first ones listed are the RGN-259 ophthalmic programme (ARISE-1, ARISE-2 and ARISE-3 in dry eye, SEER-2 in neurotrophic keratopathy) plus a recombinant thymosin beta-4 injection in acute myocardial infarction. Eye drops and cardiology, not tendons. The same database returns 2 registered studies for BPC-157^[10].

Both are prohibited in sport, under different sections

The doping status splits along the same line as the biochemistry. USADA's summary of the 2018 Prohibited List changes records that thymosin-beta4 and its derivatives, for example TB-500, were added as examples of prohibited growth factors under S2.3^[11], effective 1 January 2018. BPC-157 sits somewhere else entirely, in S0, the non-approved substances category, and the US Department of Defense Operation Supplement Safety programme states that it is an unapproved drug and cannot be legally prescribed or sold over the counter^[12]. Jurisdiction-level detail is on the regulation pages for BPC-157 in the United States and TB-500 in the United Kingdom.

What we don't yet know

No published trial has compared these compounds head to head in one protocol. For TB-500 specifically, we do not know whether the acetylated heptapeptide reproduces in people what the full-length parent does, because the registered human programme has used the parent peptide and has run it as an eye drop rather than a systemic injection. For BPC-157, the registered human record is two studies, one of which is a phase 2 hamstring-strain trial that has not reported. Long-term safety across months of continuous use has not been characterised for either in any pharmacovigilance system in our coverage area, and the identity problem is real: without a batch certificate of analysis, what is in a grey-market vial is an assumption. Thymosin alpha-1 has the deepest human record of the three, and it is also the one almost nobody in the injury-recovery market is actually buying.

Where this leaves you

Read the label sceptically. Thymosin alpha-1 and thymosin beta-4 share a name because of a 1970s calf thymus extract, not because they are chemical cousins. TB-500 is a seven-residue piece of thymosin beta-4 rather than the peptide the trials used. BPC-157 is not in the family at all and only travels with it commercially. The country-by-country position is on the regulation pages for Denmark, Germany, the Netherlands, Sweden and Norway.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed here may be classified as prescription medicines or research chemicals depending on your jurisdiction. If you are considering anything in this class, that is a conversation for a qualified healthcare professional who knows your medical history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.